Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating  the TGF-β/Smad2/3 signaling pathway Corrigendum in /10.3892/or.2023.8491

Kou,Bo; Liu,Wei; Zhao,Wei; Duan,Peng; Yang,Yang; Yi,Qiuyue; Guo,Fengwei; Li,Jianpeng; Zhou,Jinsong; Kou,Qingshan

doi:10.3892/or.2017.6012

Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway

Corrigendum in: /10.3892/or.2023.8491

Authors:
- Bo Kou
- Wei Liu
- Wei Zhao
- Peng Duan
- Yang Yang
- Qiuyue Yi
- Fengwei Guo
- Jianpeng Li
- Jinsong Zhou
- Qingshan Kou
View Affiliations

Affiliations: Department of Cadiovascular Surgery, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Urology, Xi'an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China, Department of General Surgery, Xi'an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China, The First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi’an, Shaanxi 710061, P.R. China, Medical Center, First People's Hospital of Xianyang, Xianyang, Shaanxi 712000, P.R. China
Published online on: October 2, 2017 https://doi.org/10.3892/or.2017.6012
Pages: 3592-3598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymoquinone, a major ingredient of black seed oil (Nigella sativa), has been shown to exhibit anticancer capacity in various types of cancers. However, there are few studies concerning the correlation between thymoquinone and epithelial-to-mesenchymal transition (EMT) in prostate cancer. In the present study, we firstly found that thymoquinone showed antimetastatic capacity in prostate cancer DU145 and PC3 cells. Additionally, thymoquinone reversed EMT by increasing E-cadherin expression and decreasing vimentin and Slug expression in a concentration-dependent manner. Recent studies have shown that the transforming growth factor-β (TGF-β) signaling pathway may be associated with EMT. Intriguingly, the expression of TGF-β, Smad2 and Smad3 at the mRNA and protein levels was notably reduced upon thymoquinone treatment in prostate cancer DU145 and PC3 cells. Subsequently, we confirmed that thymoquinone repressed metastasis and EMT of prostate cancer through downregulation of the TGF-β/Smad2/3 signaling pathway, which may be partially reversed by TGF-β overexpression. In summary, our findings demonstrated that thymoquinone suppressed the metastatic phenotype and reversed EMT of prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. These findings suggest that thymoquinone is a potential therapeutic agent against prostate cancer which functions by targeting TGF-β.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, et al: Local therapy improves survival in metastatic prostate cancer. Eur Urol. 72:118–124. 2017. View Article : Google Scholar : PubMed/NCBI
3	Mao XY, Li QQ, Gao YF, Zhou HH, Liu ZQ and Jin WL: Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis. Cancer Lett. 381:133–137. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cha YH, Yook JI, Kim HS and Kim NH: Catabolic metabolism during cancer EMT. Arch Pharm Res. 38:313–320. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hossen MJ, Yang WS, Kim D, Aravinthan A, Kim JH and Cho JY: Thymoquinone: An IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities. Sci Rep. 7:429952017. View Article : Google Scholar : PubMed/NCBI
6	Dur A, Kose H, Kocyigit A, Kocaman O, Ismayilova M and Sonmez FC: The anti-inflammatory and antioxidant effects of thymoquinone on ceruleine induced acute pancreatitis in rats. Bratisl Lek Listy. 117:614–618. 2016.PubMed/NCBI
7	Relles D, Chipitsyna GI, Gong Q, Yeo CJ and Arafat HA: Thymoquinone promotes pancreatic cancer cell death and reduction of tumor size through combined inhibition of histone deacetylation and induction of histone acetylation. Adv Prev Med. 2016:14078402016. View Article : Google Scholar : PubMed/NCBI
8	Acharya BR, Chatterjee A, Ganguli A, Bhattacharya S and Chakrabarti G: Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells. Biochimie. 97:78–91. 2014. View Article : Google Scholar : PubMed/NCBI
9	Mohamed AM, Refaat BA, El-Shemi AG, Kensara OA, Ahmad J and Idris S: Thymoquinone potentiates chemoprotective effect of Vitamin D3 against colon cancer: A pre-clinical finding. Am J Transl Res. 9:774–790. 2017.PubMed/NCBI
10	Salim LZ, Othman R, Abdulla MA, Al-Jashamy K, Ali HM, Hassandarvish P, Dehghan F, Ibrahim MY, Omer FA and Mohan S: Thymoquinone inhibits murine leukemia WEHI-3 cells in vivo and in vitro. PLoS One. 9:e1153402014. View Article : Google Scholar : PubMed/NCBI
11	Xu D, Ma Y, Zhao B, Li S, Zhang Y, Pan S, Wu Y, Wang J, Wang D, Pan H, et al: Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncol Rep. 31:2063–2070. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang L, Bai Y and Yang Y: Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB. Oncol Lett. 12:2840–2845. 2016. View Article : Google Scholar : PubMed/NCBI
13	Woo CC, Hsu A, Kumar AP, Sethi G and Tan KH: Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: The role of p38 MAPK and ROS. PLoS One. 8:e753562013. View Article : Google Scholar : PubMed/NCBI
14	Zhu WQ, Wang J, Guo XF, Liu Z and Dong WG: Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro. World J Gastroenterol. 22:4149–4159. 2016. View Article : Google Scholar : PubMed/NCBI
15	Koka PS, Mondal D, Schultz M, Abdel-Mageed AB and Agrawal KC: Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: Role of reactive oxygen species. Exp Biol Med. 235:751–760. 2010. View Article : Google Scholar
16	Chen W, Zhou S, Mao L, Zhang H, Sun D, Zhang J, Li J and Tang JH: Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis. Tumour Biol. 37:10011–10019. 2016. View Article : Google Scholar : PubMed/NCBI
17	Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB and Liu M: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP and Reddy GP: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 67:7782–7788. 2007. View Article : Google Scholar : PubMed/NCBI
19	Dirican A, Erten C, Atmaca H, Bozkurt E, Kucukzeybek Y, Varol U, Tarhan Oktay M, Karaca B and Uslu R: Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone-and drug-resistant prostate cancer cell lines. J BUON. 19:1055–1061. 2014.PubMed/NCBI
20	Iskender B, Izgi K, Hizar E, Jauch J, Arslanhan A, Yuksek EH and Canatan H: Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling. Tumour Biol. 37:8281–8291. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhou Q, Zheng X, Chen L, Xu B, Yang X, Jiang J and Wu C: Smad2/3/4 pathway contributes to TGF-β-induced miRNA-181b expression to promote gastric cancer metastasis by targeting Timp3. Cell Physiol Biochem. 39:453–466. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zimmerman KA, Xing D, Pallero MA, Lu A, Ikawa M, Black L, Hoyt KL, Kabarowski JH, Michalak M and Murphy-Ullrich JE: Calreticulin regulates neointima formation and collagen deposition following carotid artery ligation. J Vasc Res. 52:306–320. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ren X, Bo Y, Fan J, Chen M, Xu D, Dong Y, He H, Ren X, Qu R, Jin Y, et al: Dalbergioidin ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Mediators Inflamm. 2016:51475712016. View Article : Google Scholar : PubMed/NCBI
24	Tennant BR, Chen J, Shih AZ, Luciani DS and Hoffman BG: Myt3 mediates laminin-V/integrin-β1-induced Islet-cell migration via Tgfbi. Mol Endocrinol. 29:1254–1268. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zhao J, Cheng Q, Ye P, Yang G, Liu S, Ao Q, Liu Y and Hu Y: Atorvastatin improves pathological changes in the aged kidney by upregulating peroxisome proliferator-activated receptor expression and reducing matrix metalloproteinase-9 and transforming growth factor-β1 levels. Exp Gerontol. 74:37–42. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhang L, Cheng X, Gao Y, Zhang C, Bao J, Guan H, Yu H, Lu R, Xu Q and Sun Y: Curcumin inhibits metastasis in human papillary thyroid carcinoma BCPAP cells via down-regulation of the TGF-β/Smad2/3 signaling pathway. Exp Cell Res. 341:157–165. 2016. View Article : Google Scholar : PubMed/NCBI
27	Ouanouki A, Lamy S and Annabi B: Anthocyanidins inhibit epithelial-mesenchymal transition through a TGFβ/Smad2 signaling pathway in glioblastoma cells. Mol Carcinog. 56:1088–1099. 2017. View Article : Google Scholar : PubMed/NCBI